Drug Discovery · Allschwil, Switzerland · Founded 2019 · Privately Held (backing)
Operator of a clinical-stage biopharmaceutical company intended to offer various treatments for cancer and fibrotic diseases. Alentis Therapeutics is based in Allschwil, Switzerland and was founded in 2019. It has raised $362 million across 2 recorded rounds; the latest was an $181 million Series D in Nov 2024.
Last price · $/share
—
Implied valuation
—
Total raised
$362.5M
Last round
Later Stage VC (Series D)
Nov 2024
No prints on record
No secondary trades in Alentis Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Alentis Therapeutics with a free account
·The complete investor list: 21 names
·Watch Alentis Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Alentis Therapeutics stock.
